Jyoti Nangalia

Jyoti Nangalia

UNVERIFIED PROFILE

Are you Jyoti Nangalia?   Register this Author

Register author
Jyoti Nangalia

Jyoti Nangalia

Publications by authors named "Jyoti Nangalia"

Are you Jyoti Nangalia?   Register this Author

31Publications

1085Reads

6Profile Views

Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat.

Exp Hematol 2019 11 26;79:26-34. Epub 2019 Sep 26.

Blood Cancer Research Group, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom; Centre for Medical Education, Queen's University Belfast, Belfast, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2019.09.025DOI Listing
November 2019

Genome Sequencing during a Patient's Journey through Cancer.

N Engl J Med 2019 11;381(22):2145-2156

From the Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, and Wellcome-MRC Cambridge Stem Cell Institute and Cambridge Institute for Medical Research, the Department of Haematology, University of Cambridge, and the Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge - all in the United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1910138DOI Listing
November 2019

Clonal approaches to understanding the impact of mutations on hematologic disease development.

Blood 2019 03 6;133(13):1436-1445. Epub 2019 Feb 6.

Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-11
Publisher Site
http://dx.doi.org/10.1182/blood-2018-11-835405DOI Listing
March 2019

No place for 'trial by media' in bullying allegations.

Nature 2018 12;564(7735):190

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41586-018-07723-0DOI Listing
December 2018

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

N Engl J Med 2018 10;379(15):1416-1430

From the Wellcome-MRC Cambridge Stem Cell Institute and Cambridge Institute for Medical Research (J.G., C.E.M., F.L.N., A.R.G., P.J.C.), the Department of Haematology, University of Cambridge (J.G., E.J.B., C.M., J.C., C.E.M., F.L.N., A.R.G.), and the Department of Haematology, Cambridge University Hospitals NHS Foundation Trust (J.G., E.J.B., A.L.G., C.M., J.C., A.R.G.), Cambridge, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus (J.N., D.C.W., N.A., E.P., G.G., L.O., S.O., J.W.T., A.P.B., N.W., P.J.C.), and the European Molecular Biology Laboratory, European Bioinformatics Institute (R.C., M.G.), Hinxton, Big Data Institute, University of Oxford, Oxford (D.C.W.), the Department of Haematology, Queen's University Belfast, Belfast (M.F.M.), and the Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London (C.N.H.) - all in the United Kingdom; the Center for Molecular Oncology and the Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York (E.P., G.G.); the Department of Hematology, Zealand University Hospital, Roskilde, and the University of Copenhagen, Copenhagen (C.L.A., H.C.H.); and the Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy (P.G., A.M.V.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1716614
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1716614DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030948PMC
October 2018

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

J Clin Oncol 2018 Aug 28:JCO2018788414. Epub 2018 Aug 28.

Anna L. Godfrey, Jacob Grinfeld, and Anthony R. Green, Cambridge University Hospitals National Health Service (NHS) Foundation Trust; Peter J. Campbell and Jyoti Nangalia, Wellcome Trust Sanger Institute, Hinxton; Cathy MacLean, Julia Cook, Julie Temple, and Anthony R. Green, University of Cambridge; Anthony R. Green, Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge; Georgina Buck, University of Oxford, Oxford; Bridget S. Wilkins and Claire N. Harrison, Guy's and St Thomas' NHS Foundation Trust, London; Keith Wheatley, University of Birmingham, Birmingham; Mary Frances McMullin, Queen's University Belfast, Belfast, United Kingdom; Cecily Forsyth, Gosford Hospital, Gosford, and Australasian Leukaemia and Lymphoma Group, Australia; and Jean-Jacques Kiladjian, Hôpital Saint-Louis, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.8414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269131PMC
August 2018

Myeloproliferative neoplasms: from origins to outcomes.

Blood 2017 12;130(23):2475-2483

Department of Haematology, Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, United Kingdom; and.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2017-06
Publisher Site
http://dx.doi.org/10.1182/blood-2017-06-782037DOI Listing
December 2017

Myeloproliferative neoplasms: from origins to outcomes.

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):470-479

Department of Haematology, Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, United Kingdom; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142568PMC
December 2017

Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.

Haematologica 2017 01 1;102(1):7-17. Epub 2016 Dec 1.

Department of Haematology, Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.113845DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210228PMC
January 2017

Pathogenesis of Myeloproliferative Disorders.

Annu Rev Pathol 2016 05;11:101-26

Department of Haematology, Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge CB2 0XY, United Kingdom; email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-pathol-012615-044454DOI Listing
May 2016

Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms.

J Clin Pathol 2016 Feb 19;69(2):155-63. Epub 2015 Aug 19.

School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia, Australia PathWest Laboratory Medicine, Western Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2015-203177DOI Listing
February 2016

RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.

Cell Rep 2015 Dec 10;13(11):2345-2352. Epub 2015 Dec 10.

Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; Broad Institute of the Massachusetts Institute of Technology and Harvard, 415 Main Street, Cambridge, MA 02142; Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.11.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691544PMC
December 2015

DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

Haematologica 2015 Nov 6;100(11):e438-42. Epub 2015 Aug 6.

Department of Haematology, Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK Department of Haematology, Addenbrooke's Hospital, Cambridge, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.129510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825297PMC
November 2015

Effect of mutation order on myeloproliferative neoplasms.

N Engl J Med 2015 Feb;372(7):601-612

Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council Stem Cell Institute (C.A.O., D.G.K., J.N., Y.S., J.G., E.J.B., C.E.M., A.L.G., D.D., A.R.G.) and Department of Hematology (C.A.O., D.G.K., J.N., Y.S., J.G., E.J.B., C.E.M., A.L.G., D.D., G.S.V., P.J.C., A.R.G.), University of Cambridge, Department of Haematology, Addenbrooke's Hospital (C.A.O., J.N., J.G., E.J.B., A.L.G., G.S.V., P.J.C., A.R.G.), Wellcome Trust Sanger Institute (D.C.W., E.P., G.S.V., P.J.C.), and Cancer Research U.K. Cambridge Institute, Li Ka Shing Centre (S.M.), Cambridge, and Guy's and St. Thomas' National Health Service Foundation Trust, Guy's Hospital, London (C.N.H.) - all in the United Kingdom; Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Florence, Italy (P.G., A.V.); Departments of Pathology (B.B.) and Hematology (C.B.), Hospital del Mar, Barcelona; and the Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany (K.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1412098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660033PMC
February 2015

Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.

Leuk Res 2015 Jan 29;39(1):82-7. Epub 2014 Nov 29.

Faculty of Medicine, University of Southampton, Southampton, UK; Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2014.11.019DOI Listing
January 2015

The evolving genomic landscape of myeloproliferative neoplasms.

Hematology Am Soc Hematol Educ Program 2014 Dec 18;2014(1):287-96. Epub 2014 Nov 18.

Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, Department of Haematology, University of Cambridge, Cambridge, United Kingdom; and Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2014.1.287DOI Listing
December 2014

Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?

Blood 2014 Nov;124(22):3332-4

Cambridge Institute for Medical Research and Wellcome Trust/Medical Research Council, Stem Cell Institute and Department of Haematology, University of Cambridge, Cambridge, United Kingdom Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-09-603043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239339PMC
November 2014

JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.

Proc Natl Acad Sci U S A 2014 Oct 6;111(42):15190-5. Epub 2014 Oct 6.

Cambridge Institute for Medical Research, Medical Research Council/Wellcome Trust Cambridge Stem Cell Institute, and Department of Haematology, University of Cambridge, Cambridge CB2 0XY, United Kingdom; Department of Haematology, Addenbrooke's Hospital, Cambridge CB2 0XY, United Kingdom; and

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1401873111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210350PMC
October 2014

CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum.

Am J Hematol 2014 May 11;89(5):453-6. Epub 2014 Mar 11.

Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23678DOI Listing
May 2014

JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.

Blood 2014 May 1;123(20):3139-51. Epub 2014 Apr 1.

Cambridge Institute for Medical Research and Wellcome Trust/Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, United Kingdom; Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom;

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2013-06-51
Publisher Site
http://dx.doi.org/10.1182/blood-2013-06-510222DOI Listing
May 2014

Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support.

Leuk Lymphoma 2008 Aug;49(8):1530-6

Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190802210718DOI Listing
August 2008

Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex.

Proc Natl Acad Sci U S A 2008 Mar 24;105(12):4661-6. Epub 2008 Mar 24.

Department of Haematology, Division of Structural Medicine, Thrombosis Research Unit, Cambridge Institute for Medical Research, University of Cambridge, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 0XY, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0711055105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2290767PMC
March 2008